2 citations
,
June 2024 in “Journal of Clinical Medicine” This study identifies various nail changes in alopecia areata, which can affect quality of life, and suggests that while spontaneous improvement is possible, further research is needed to refine treatment strategies.
April 2024 in “International journal of molecular sciences” This study examines the similarities and differences in the pathogenesis of autoimmune conditions alopecia areata and vitiligo, highlighting shared features like immune cell involvement and cytokine pathways, while noting differing immune responses in skin and hair.
1 citations
,
August 2023 in “Biomolecules” This study found that patients with alopecia areata and their healthy family members had elevated levels of Th1- and Th17-related cytokines, suggesting a genetic link in cytokine dysregulation.
51 citations
,
July 2023 in “American Journal of Clinical Dermatology” 30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.
8 citations
,
October 2022 in “Dermatologic Therapy” In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.
2 citations
,
August 2022 in “Frontiers in Immunology” This study reported significant hair regeneration in a 3-year-old with severe alopecia areata after six months of treatment with microneedling and compound betamethasone.
31 citations
,
July 2022 in “Advanced healthcare materials/Advanced Healthcare Materials” In this study, researchers developed a drug-free microneedle patch using chitosan lactate and stem cell-derived exosomes that significantly promotes hair regeneration in animal tests compared to minoxidil, highlighting its potential as a simple and efficient hair loss treatment.
16 citations
,
January 2022 in “International journal of molecular sciences” This review summarizes the influences of lifestyle factors such as smoking, alcohol, and diet on the pathogenesis of alopecia areata but reports no new clinical results.
37 citations
,
December 2021 in “Cells” This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This study found that alopecia areata patients had higher baseline interleukin levels, which significantly decreased with tofacitinib treatment, though this change did not correspond to disease severity improvement.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.
50 citations
,
May 2021 in “Frontiers in immunology” This review discusses how tissue resident memory T cells contribute to autoimmune skin diseases like vitiligo and psoriasis, highlighting their role in continuous immune activation, and reports no new clinical results.
42 citations
,
February 2021 in “Signal Transduction and Targeted Therapy” This review discusses potential cell sources and bioengineering strategies for regenerating hair follicles with functional cycling, reporting no new results.
15 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” This review discusses the potential use of platelet-rich plasma for treating alopecia areata but reports no new experimental findings, noting the need for standardized protocols and larger studies to evaluate its efficacy.
23 citations
,
September 2020 in “Journal of Dermatological Science” This pilot study suggests that skin-resident γδT-cells may play a significant role in the early stages of alopecia areata pathogenesis, indicating a potential new target for therapeutic management.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.
65 citations
,
July 2020 in “Science Advances” Dermal exosomes with miR-218-5p boost hair growth by controlling β-catenin signaling.
134 citations
,
July 2020 in “Experimental dermatology” This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.
19 citations
,
July 2020 in “EBioMedicine” In this study, the researchers identified a variant in the CCHCR1 gene associated with an alopecia areata subtype characterized by impaired keratinization and autoimmune events.
3 citations
,
March 2020 in “International Journal of Dermatology” This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.
67 citations
,
January 2020 in “Cellular & Molecular Immunology/Cellular & molecular immunology” This review discusses the dual role of tissue-resident memory T cells in providing immune protection against infections and cancer and contributing to autoimmune skin disease pathology, without presenting new experimental results.
14 citations
,
January 2020 in “Advances in Dermatology and Allergology” This study found that elevated serum levels of IL-15 in active alopecia areata patients are correlated with disease severity, suggesting it plays a role in disease pathogenesis.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” This study suggests that intralesional triamcinolone acetonide at a concentration of 5 mg/mL may offer the best balance of effectiveness and safety for treating focal alopecia areata.
24 citations
,
October 2019 in “Biomaterials Research” This study investigated the use of Minoxidil encapsulated in HA-PLGA nanoparticles for alopecia treatment and found that these nanoparticles efficiently delivered the drug to hair follicle cells without significant cytotoxicity, offering a potential transdermal delivery method for various diseases.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.
23 citations
,
September 2019 in “Dermatology practical & conceptual” This study analyzed the features of alopecia areata incognita and diffuse alopecia areata, finding distinct patterns in hair loss regions and trichoscopic signs, and noted a benign course responsive to topical steroid therapy.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
14 citations
,
August 2019 in “Dermatologic Therapy” This letter to the editor comments on new-onset alopecia areata during secukinumab therapy but presents no new research findings.
26 citations
,
July 2019 in “JAAD Case Reports” This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.
19 citations
,
May 2019 in “Journal of Cosmetic Dermatology” In this study, both platelet-rich plasma and intralesional corticosteroids improved hair re-growth in alopecia areata patients, but the difference between treatments was not significant, with fewer relapses observed in the platelet-rich plasma group.
9 citations
,
May 2019 in “Journal of dermatological treatment” This article reviews characteristics and mental health impacts of alopecia areata but provides no new clinical findings; future research is encouraged.
57 citations
,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.
101 citations
,
March 2019 in “Cell Stem Cell” This study found that Oncostatin M, via JAK-STAT5 signaling, keeps hair follicle stem cells inactive, and its removal leads to hair growth initiation in mice.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.
14 citations
,
January 2019 in “PubMed” This review examines the potential roles of vitamin D in the pathogenesis of alopecia areata and suggests that vitamin D analogs like calcipotriol may have therapeutic potential.
148 citations
,
December 2018 in “Journal of autoimmunity” This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.
49 citations
,
December 2018 in “JAAD case reports” This case report describes a patient who developed alopecia after 18 weeks of treatment with dupilumab for atopic dermatitis.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
29 citations
,
November 2018 in “Journal of The European Academy of Dermatology and Venereology” This study found that anxiety-related traits significantly predict the impact of hair loss on quality of life across different alopecia types, with variations observed based on gender.
25 citations
,
October 2018 in “Pediatric dermatology” In this study, three pediatric patients with alopecia areata demonstrated hair regrowth after being treated with ustekinumab.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This editorial proposes a new classification for alopecia areata that incorporates the SALT score and body hair involvement, aiming to improve the assessment and treatment outcomes.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.
89 citations
,
August 2018 in “JAMA Dermatology” This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.
27 citations
,
April 2018 in “Journal of autoimmunity” In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.
45 citations
,
January 2018 in “International Journal of Dermatology” This review explores nail changes associated with alopecia areata, noting their prevalence and impact on appearance and function, but reports no new clinical findings; the authors call for larger controlled trials.
19 citations
,
January 2018 Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.
102 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
58 citations
,
December 2017 in “Journal of The European Academy of Dermatology and Venereology” This review highlights that microneedling shows some promise for improving hair growth in alopecia, particularly when used with other treatments, though more research is needed to establish its efficacy and protocols.
113 citations
,
November 2017 in “Scientific Reports” This study found that treatment with mesenchymal stem cell extracellular vesicles enhanced hair growth in mice and stimulated dermal papilla cell activity and growth factor production in vitro.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.
19 citations
,
August 2017 in “American journal of clinical dermatology” This analysis reports that hepatitis B surface protein antigen exposure is associated with an increased risk of alopecia areata.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.
63 citations
,
May 2017 in “American Journal of Clinical Dermatology” This review found that patients with alopecia areata may have lower levels of vitamin D, zinc, and folate, but conflicting evidence precludes definitive clinical recommendations for micronutrient supplementation.
14 citations
,
March 2017 in “Genes and immunity” Certain microRNAs may help treat alopecia areata by targeting immune pathways.
23 citations
,
February 2017 in “Journal of dermatology” This meta-analysis suggests that patients with alopecia areata have lower serum levels of zinc and selenium compared to healthy controls, which may be important risk factors for the condition.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
16 citations
,
November 2016 in “Journal of Cosmetic and Laser Therapy” This review highlights that laser and light treatments could serve as safe and effective alternatives to current therapies for alopecia areata, with the excimer laser showing positive results, though further randomized controlled trials are necessary to establish optimal treatment protocols.
62 citations
,
October 2016 in “Dermatologic Therapy” This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
29 citations
,
June 2016 in “Experimental Dermatology” This study provides suggestive evidence that duplications in the MCHR2 gene may be involved in the pathogenesis of alopecia areata.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.
295 citations
,
May 2016 in “Journal of the American Academy of Dermatology” This review examines the immunological aspects of alopecia areata, focusing on genetic, neuroimmunological, and immune privilege factors, but does not report new clinical findings.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.
36 citations
,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” This article reviews the role of vasoactive intestinal peptide in maintaining immune privilege in hair follicles and does not report new findings; the authors propose it as essential for immune homeostasis in alopecia areata.
12 citations
,
March 2016 in “BBA clinical” This study found that intracellular Toll-like receptors were significantly up-regulated in peripheral blood mononuclear cells of alopecia areata patients, suggesting a potential role in inflammatory signaling and pathogenesis.
82 citations
,
March 2016 in “Autoimmunity reviews” This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.
5 citations
,
February 2016 in “Hanbang an i bi inhu pibugwa hakoeji/Hanbang an'i'bi'in'hu pibu'gwa haghoeji” This study found that HRHDT combined with microneedle therapy improved hair growth in a mouse model of alopecia more effectively than microneedle therapy alone.
65 citations
,
December 2015 in “Experimental dermatology” This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.
52 citations
,
July 2015 in “International Journal of Dermatology” This study found that patients with alopecia areata had significantly lower serum zinc levels, which correlated inversely with disease severity, duration, and resistance to therapies, suggesting zinc assessment as a marker of disease status.
184 citations
,
February 2015 in “EBioMedicine” This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.
62 citations
,
January 2015 in “Journal of Dermatological Science” This review summarizes the current genetic research on alopecia areata, including potential new therapeutic strategies, but reports no new clinical findings.
36 citations
,
January 2015 in “Dermatology” In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.
175 citations
,
December 2014 in “PLoS Biology” This study found that macrophages near hair follicles contribute to the activation of skin epithelial stem cells in mice, suggesting a novel role for macrophages in regulating hair growth.
35 citations
,
December 2014 in “Clinical and experimental dermatology” This study found that patients with alopecia areata had reduced erythrocyte SOD and GSH-Px activities and elevated plasma MDA levels, suggesting a potential role of oxidative stress in the disease's pathogenesis.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
37 citations
,
October 2014 in “JAMA dermatology” This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
69 citations
,
August 2014 in “Journal of The American Academy of Dermatology” This review discusses recent advances in trichoscopy for differentiating types of alopecia and presents a systematic approach for using its diagnostic findings, but reports no new clinical results.
3 citations
,
February 2014 in “Dong-ui saengni byeongni hakoeji” This study found that micro needle roller therapy enhanced hair follicle development and increased growth factor expression in C57BL/6 mice, suggesting potential benefits for alopecia treatment.
53 citations
,
January 2014 in “Journal of Cutaneous and Aesthetic Surgery” Microneedling combined with triamcinolone can safely stimulate faster hair regrowth in people with Alopecia Areata.
27 citations
,
January 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” This study identified somatostatin as a potential secretory factor contributing to the immune privilege of human hair follicles.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
24 citations
,
January 2012 in “Indian Journal of Dermatology, Venereology and Leprology” This study suggests that hypersensitivity and increased serum IgE levels might contribute to the pathogenesis of diffuse alopecia areata through intense local inflammatory infiltration.
47 citations
,
December 2011 in “Experimental Dermatology” This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.
14 citations
,
November 2011 in “Journal of The American Academy of Dermatology” This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.
48 citations
,
September 2011 in “British Journal of Dermatology” This study found that DNA methylation and histone modification status were altered in peripheral blood mononuclear cells of patients with alopecia areata, suggesting these changes may contribute to the disease's pathological immune responses.
43 citations
,
May 2011 in “Dermatologic therapy” This study identified at least eight genetic regions associated with alopecia areata, which may lead to the development of new targeted therapies based on these findings.
109 citations
,
May 2011 in “Dermatologic Therapy” This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
35 citations
,
March 2010 in “Journal of Dermatological Science” Ebastine may help regrow hair in alopecia areata patients.
391 citations
,
January 2010 in “Journal of The American Academy of Dermatology” This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.
43 citations
,
November 2009 in “Archives of dermatology” This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.
60 citations
,
October 2009 in “Dermatology” This article proposes a hypothesis for alopecia areata hair loss patterns and provides epidemiological evidence supporting distinct hair loss characteristics between general cases and those with androgenetic alopecia; it presents no new clinical results.
36 citations
,
June 2009 in “Archives of Dermatology” This text is an informational content piece about JAMA Dermatology's website and does not contain any research findings or conclusions.
65 citations
,
January 2009 in “Annals of Dermatology” In this study, oral zinc supplementation for twelve weeks increased serum zinc levels in alopecia areata patients with low zinc, showing positive hair regrowth in 66.7% of participants, though this was not statistically significant.
42 citations
,
March 2008 in “Molecular and Cellular Endocrinology” This review explores the potential (neuro-)endocrine influences on hair follicle epithelial stem cell biology and emphasizes the need for more systematic research, but it provides no new empirical results.
253 citations
,
December 2007 in “Journal of Investigative Dermatology” This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.
36 citations
,
July 2007 in “Journal of Investigative Dermatology” This study observed a strong negative association between the HLA-DQB1*0201 allele and the alopecia totalis/alopecia universalis phenotype in Caucasian individuals, indicating a potential protective role.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.
489 citations
,
June 2005 in “The FASEB Journal” This study found that human scalp hair follicles can respond to corticotropin releasing hormone stimulation similarly to the classical HPA axis, including up-regulating cortisol production and activating neuroendocrine feedback loops.
163 citations
,
November 2003 in “Journal of Investigative Dermatology” This study found that women with androgenetic alopecia or alopecia areata have significantly lower serum ferritin levels than those without hair loss, suggesting a potential link between these types of alopecia and decreased iron stores.
69 citations
,
July 2002 in “Clinical and Experimental Dermatology” This review discusses rodent models of alopecia areata and highlights genetic and epigenetic factors influencing its development, but reports no new experimental results.
14 citations
,
March 2002 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that serum MIF levels were significantly higher in patients with extensive alopecia areata compared to those with mild alopecia areata and healthy individuals.
22 citations
,
February 2000 in “Journal of the American Academy of Dermatology” Eosinophils are not a reliable marker for diagnosing alopecia areata.
127 citations
,
January 2000 in “Journal of Investigative Dermatology” This study found that pro-inflammatory cytokines and apoptotic mechanisms, specifically involving granzyme B and Fas pathways, are associated with chronic alopecia areata, indicating their potential role in the disease's persistence.
65 citations
,
September 1999 in “The Journal of Dermatology” In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.
1113 citations
,
August 1999 in “The New England Journal of Medicine” This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.
132 citations
,
November 1998 in “Journal of the American Academy of Dermatology” This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.
64 citations
,
July 1997 in “Journal of The American Academy of Dermatology” This study found that eosinophils are a useful diagnostic feature for alopecia areata, especially when the typical "swarm of bees" lymphoid infiltrate is absent, helping differentiate it from trichotillomania.
101 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.
104 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
75 citations
,
September 1971 in “British Journal of Dermatology” This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.
